Flow diagram showing the number of patients in the study and their outcomes.

<p>* Treatment duration was not reported in one patient. This patient was excluded from the analysis on treatment duration.</p

Post-kala- azar dermal leishmaniasis grading system.

<p>Post-kala- azar dermal leishmaniasis grading system.</p

Treatment duration for patients with post-kala-azar dermal leishmaniasis treated by Médecins Sans Frontières in South Sudan from 2002 to 2008.

<p>Treatment duration for patients with post-kala-azar dermal leishmaniasis treated by Médecins Sans Frontières in South Sudan from 2002 to 2008.</p

Demographic and baseline clinical characteristics of patients with post-kala-azar dermal leishmaniasis treated by Médecins Sans Frontières in South Sudan from 2002 to 2008.

<p>Demographic and baseline clinical characteristics of patients with post-kala-azar dermal leishmaniasis treated by Médecins Sans Frontières in South Sudan from 2002 to 2008.</p

Area under the curve for children and adolescents scoring.

<p>Area under the curve for children and adolescents scoring.</p

Probabilities of death^a at each score for adults (≥ 19 years), and children and adolescents (< 19 years)^b.

<p>Probabilities of death<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005921#t005fn001" target="_blank">^a</a> at each score for adults (≥ 19 years), and children and adolescents (< 19 years)<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005921#t005fn002" target="_blank">^b</a>.</p

Area under the curve for adults scoring.

<p>Area under the curve for adults scoring.</p

Performance of the severity scoring for prediction of death in VL patients in South Sudan.

<p>Performance of the severity scoring for prediction of death in VL patients in South Sudan.</p

Severity scoring for adults (≥ 19 years), and children and adolescents (< 19 years).

<p>Severity scoring for adults (≥ 19 years), and children and adolescents (< 19 years).</p

Risk factors for death among child and adolescent patients (<19 years old).

<p>Risk factors for death among child and adolescent patients (<19 years old).</p